HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Gold Bond menthol medicated lotion backed by $19 mil. ad budget through 1999.

This article was originally published in The Rose Sheet

Executive Summary

CHATTEM GOLD BOND MEDICATED LOTION $19 MIL. AD BUDGET includes $4 mil. for promotional spots breaking in October and running through the end of December, and $15 mil. for ads in 1999, Chattem said. The campaign, supporting the largest launch in the company's history, will consist primarily of TV commercials on a mix of stations and during a variety of times, according to the company. The firm also plans to run print spots. Designed by Los Angeles-based DFI, the spots emphasize the point of difference between Gold Bond's medicated formula and ordinary lotions, according to Chattem. Triple Action Gold Bond Medicated Lotion and Extra Strength Medicated Lotion "moisturize dry skin, relieve itchy skin and soothe and protect," Chattem said.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel